Our world-leading immunoglobulin (Ig) franchise includes an intravenous and a subcutaneous option and is the cornerstone for CSL Behring's neurology therapeutic treatments. Our efforts in this area focus on bringing trusted products and technologies to serve patients with a rare and serious neurologic disease: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).